top of page
2020 HIV DIAGNOSTICS

23. Recommit to offering a $20 all-inclusive price per test (covering instrument, connectivity, service and maintenance) for the m-PIMA qualitative (EID) and viral load assays based on minimum volume thresholds.

Updates

-

2018 HIV DIAGNOSTICS

60. Move to a new pricing model for the Point of Care (POC) m-PIMA molecular diagnostic system for EID and VL assays that is an all inclusive price (including instrument, data services, connectivity, service and maintenance) of $30 per test, moving down to $15 per test with sufficient aggregate EID and VL volumes.

61. To complement existing HIV, viral hepatitis, TB, haemorrhagic fever and other important infectious disease assays, Abbott will to continue to develop additional assays of strategic importance across the platforms.

62. Commit to coordinate across business divisions to provide the most comprehensive solution of centralized and decentralized molecular platforms for each country.

63. Continue to implement consistent and transparent pricing, communicating openly on volume requirements for pricing levels.

Updates

Commitments 60 & 61:

VL for mPima received WHO prequalification.

Commitment 63:

Now offering a 20/cartridge all in cost, in some countries including delivery or cartridge to site level.

22. Make every effort to stay in the EID market to ensure there is a sufficient testing capacity to reach and maintain accelerated Fast Track targets (95% of HEI tested by 2020 and beyond).

23. Ensure consistent reagent pricing across partners within countries and within regions, and provide a transparent breakdown of pricing for the products and services sold.

24. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, ideally all-inclusive pricing models.

25. Provide service level agreements that clearly spell out key performance indicators POC, near POC, and high-throughput laboratory instruments, including target up-times and failure rate threshold (with consideration for different causes), plus a mitigation plan when the threshold is exceeded.

26. Consider the inclusion of a clinical indeterminate range in test result reports for more accurate diagnosis of infants per WHO guidelines.

27. Rapidly communicate stock shortages with major buyers and work on joint mitigation strategies.

Updates

-

2020 TB DIAGNOSTICS

32. Prioritize the pediatric TB diagnostic space to ensure there are improved tools for pediatric TB infection and disease detection to reach and maintain targets.

33. Develop quality-assured, affordable, less invasive alternative specimen processing methods or products (not based only on sputum) that can be used for the pediatric population, such as urine, stool or saliva.

34. Ensure diagnostic studies include children and alternative (non-sputum-based) sample types.

35. Expedite development of point-of-care biomarker-based tests for infants and children.

36. Consider moving from separate instrument, consumable, and service procurement towards more consolidated, all-inclusive pricing models, for both laboratory-based and point-of-care technologies.

37. Provide service level agreements that clearly spell out key performance indicators for all technology types and their offered service plans, plus a mitigation plan when the threshold is exceeded.

 

51.Develop a new, more sensitive lateral flow TB LAM RDT with a broader indication for use including in TB without HIV co-infection in both adults and children.

52. Offer access pricing for TB testing for laboratory-based, high-throughput devices to complement decentralized testing, which will include pursuing WHO PQ (when relevant for TB) as well as the WHO guidance and recommendation process.

Updates

-

bottom of page